Want to see NUVB full AI Analyst Report?
NUVB Stock Chart & Stats
$6.42
-$0.07(-1.08%)
At close: 4:00 PM EDT
$6.42
-$0.07(-1.08%)
Day’s Range― - ―
52-Week Range$2.57 - $9.75
Previous CloseN/A
Volume6.14M
Average Volume (3M)8.03M
Market Cap
$2.45B
Enterprise Value$1.74K
Total Cash (Recent Filing)$660.96M
Total Debt (Recent Filing)$252.14M
Price to Earnings (P/E)―
Beta1.69
Next Earnings
Nov 11, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.43
Shares Outstanding351,123,230
10 Day Avg. Volume6,156,846
30 Day Avg. Volume8,034,544
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)10.01
Price to Sales (P/S)48.65
P/FCF Ratio-17.61
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$14.86Price Target Upside131.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.39
Revenue Forecast (FY)$201.15M
Bulls Say, Bears Say
Bulls Say
High Gross Margins And Scaling RevenueVery high gross margins (~92%) alongside meaningful revenue scaling indicate strong unit economics that can support durable profitability as sales grow. These margins give management flexibility to invest in commercialization and R&D while the business transitions toward operating leverage over the next 2–6 months.
Market Leadership In ROS1 First-lineClear first‑line share leadership and rapid new patient starts suggest durable commercial adoption. Dominant positioning in a growing ROS1 market creates long‑duration revenue stacking as first‑line patients stay on therapy, reinforcing sustainable top‑line growth and payer recognition over coming quarters.
Strengthened Liquidity And Low‑cost FinancingA large cash balance plus an opportunistic, low‑coupon convertible offering materially extends runway and funds development and commercialization. Long‑dated, low‑cost financing reduces near‑term refinancing risk and supports multi‑year clinical plans while preserving operational flexibility.
Bears Say
Persistent Negative Cash FlowSustained operating and free cash outflows reflect ongoing investment in commercialization and trials and mean the company remains dependent on external financing until cash generation turns positive. That reliance elevates dilution and execution risk if revenue growth slows or costs remain elevated.
Large Reported Losses Consuming EquityDeep, persistent net losses are eroding returns on the company’s equity base and indicate capital is being consumed faster than income generation. Continued deficits can pressure shareholder equity and force further financing or dilution absent a durable path to operating breakeven.
Commercial And Regulatory HeadwindsMaterial gross‑to‑net discounts, incomplete molecular testing and community prescribing inertia constrain near‑term uptake and realized revenue. Multi‑year timelines to registrational data and endpoint uncertainty for some programs extend regulatory risk and the period before full commercial returns materialize.
Nuvation Bio News
NUVB FAQ
What was Nuvation Bio Inc’s price range in the past 12 months?
Nuvation Bio Inc lowest stock price was $2.57 and its highest was $9.75 in the past 12 months.
What is Nuvation Bio Inc’s market cap?
Nuvation Bio Inc’s market cap is $2.45B.
When is Nuvation Bio Inc’s upcoming earnings report date?
Nuvation Bio Inc’s upcoming earnings report date is Nov 11, 2026 which is in 83 days.
How were Nuvation Bio Inc’s earnings last quarter?
Nuvation Bio Inc released its earnings results on Aug 06, 2026. The company reported -$0.18 earnings per share for the quarter, missing the consensus estimate of -$0.142 by -$0.038.
Is Nuvation Bio Inc overvalued?
According to Wall Street analysts Nuvation Bio Inc’s price is currently Undervalued.
Does Nuvation Bio Inc pay dividends?
Nuvation Bio Inc does not currently pay dividends.
What is Nuvation Bio Inc’s EPS estimate?
Nuvation Bio Inc’s EPS estimate is -0.12.
How many shares outstanding does Nuvation Bio Inc have?
Nuvation Bio Inc has 351,123,230 shares outstanding.
What happened to Nuvation Bio Inc’s price movement after its last earnings report?
Nuvation Bio Inc reported an EPS of -$0.18 in its last earnings report, missing expectations of -$0.142. Following the earnings report the stock price went down -4.082%.
Which hedge fund is a major shareholder of Nuvation Bio Inc?
Currently, no hedge funds are holding shares in NUVB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nuvation Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.86 (131.42% Upside)
$14.86 (131.42% Upside)
Blogger Sentiment
Bullish
NUVB Sentiment 91%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $118.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.4%
Last 30 Days ▲ 6.9%
Last 30 Days ▲ 6.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
155.77%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
15.03%
Trailing 12-Months
Company Description
Nuvation Bio Inc
Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a poly ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.
NUVB Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive commercial and clinical trajectory: IBTROZI is demonstrating strong revenue growth, clear market leadership in first-line ROS1, exceptional clinical durability and favorable patient-reported outcomes, while safusidenib shows encouraging long-term activity and an expanded development plan. The company further strengthened its balance sheet via a well‑subscribed convertible note offering. Key near-term challenges include elevated operating expenses, gross-to-net pressure, community testing and prescribing inertia, and multi‑year timelines for Phase III readouts. Competitive entrants and dilution risk exist but were framed as manageable. On balance, the highlights (robust revenue growth, market share leadership, best-in-class clinical data, strong cash position and program expansion) materially outweigh the lowlights.View all NUVB earnings summariesNUVB Stock 12 Month Forecast
Average Price Target
$14.86
▲(131.42% Upside)
Technical Analysis
Nektar Therapeutics
―
Precigen
―
Wave Life Sciences
―
Enliven Therapeutics
―
Praxis Precision Medicines
―
Ownership Overview
24.64% Insiders
15.63% Mutual Funds
19.69% Other Institutional Investors
28.89% Public Companies and Individual Investors